Vaccination with theLeishmania infantumAcidic Ribosomal P0 Protein plus CpG Oligodeoxynucleotides Induces Protection against Cutaneous Leishmaniasis in C57BL/6 Mice but Does Not Prevent Progressive Disease in BALB/c Mice
Open Access
- 1 September 2005
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 73 (9) , 5842-5852
Abstract
We have examined the efficacy of the administration in mice of a molecularly defined vaccine based on theLeishmania infantumacidic ribosomal protein P0 (rLiP0). Two different challenge models of murine cutaneous leishmaniasis were used: (i) subcutaneous inoculation ofL. majorparasites in susceptible BALB/c mice (a model widely used for vaccination analysis) and (ii) the intradermal inoculation of a low infective dose in resistant C57BL/6 mice (a model that more accurately reproduces theL. majorinfection in natural reservoirs and in human hosts). First, we demonstrated that C57BL/6 mice vaccinated with LiP0-DNA or rLiP0 protein plus CpG oligodeoxynucleotides (ODN) were protected against the development of dermal pathology and showed a reduction in the parasite load. This protection was associated with production of gamma interferon (IFN-γ) in the dermal site. Secondly, we showed that immunization with rLiP0 plus CpG ODN is able to induce only partial protection in BALB/c, since these mice finally developed a progressive disease. Further, we demonstrated that LiP0 vaccination induces a Th1 immunological response in both strains of mice. In both cases, the antibodies against LiP0 were predominantly of the immunoglobulin G2a isotype, which was correlated with an rLiP0-stimulated production of IFN-γ in draining lymph nodes. Finally, we demonstrated that LiP0 vaccination does not prevent the Th2 response induced byL. majorinfection in BALB/c mice. Taken together, these data indicate that the BALB/c model of cutaneous leishmaniasis may undervalue the potential efficacy of some vaccines based on defined proteins, making C57BL/6 a suitable alternative model to test vaccine candidates.Keywords
This publication has 34 references indexed in Scilit:
- The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine developmentImmunological Reviews, 2004
- Recent advances in vaccines for leishmaniasisExpert Opinion on Biological Therapy, 2004
- The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgroundsInternational Journal for Parasitology, 2004
- Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up‐regulation and T cell activationEuropean Journal of Immunology, 2003
- A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantumVeterinary Immunology and Immunopathology, 2003
- The immunology of susceptibility and resistance to Leishmania major in miceNature Reviews Immunology, 2002
- Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasisImmunology Letters, 1995
- Mechanisms of Helper T‐Cell Regulation of B‐Cell ActivityaAnnals of the New York Academy of Sciences, 1993
- Recombinant interleukin 12 cures mice infected with Leishmania major.Journal of Experimental Medicine, 1993
- Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.Journal of Experimental Medicine, 1990